STOK – Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc.STOK
$7.69Name : Stoke Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $415,857,504.00
EPSttm : -1.65
Stoke Therapeutics, Inc.
$7.69
1.72%$0.13Float Short %
29.02
Margin Of Safety %
Put/Call OI Ratio
3.8
EPS Next Q Diff
-0.18
EPS Last/This Y
0.3
EPS This/Next Y
-0.66
Price
7.69
Target Price
23.88
Analyst Recom
1.2
Performance Q
-18.71
Relative Volume
1
Beta
1.15
Ticker: STOK
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-20 | STOK | 8.34 | 4.68 | 13.33 | 2748 |
| 2025-03-21 | STOK | 8.15 | 4.73 | 0.54 | 2770 |
| 2025-03-24 | STOK | 8.28 | 4.43 | 0.68 | 1503 |
| 2025-03-25 | STOK | 7.75 | 3.69 | 25.00 | 1638 |
| 2025-03-26 | STOK | 7.41 | 4.08 | 999.99 | 1800 |
| 2025-03-27 | STOK | 7.45 | 4.14 | 2.00 | 1819 |
| 2025-03-28 | STOK | 7.22 | 4.12 | 151.00 | 1819 |
| 2025-03-31 | STOK | 6.64 | 4.38 | 4.75 | 1917 |
| 2025-04-01 | STOK | 6.16 | 4.42 | 2.58 | 1929 |
| 2025-04-02 | STOK | 6.59 | 4.37 | 1.92 | 1932 |
| 2025-04-03 | STOK | 6.31 | 4.37 | 1.92 | 1932 |
| 2025-04-04 | STOK | 5.93 | 4.18 | 999.99 | 1948 |
| 2025-04-07 | STOK | 5.99 | 4.14 | 999.99 | 1932 |
| 2025-04-08 | STOK | 5.91 | 4.11 | 0.00 | 1922 |
| 2025-04-09 | STOK | 6.43 | 4.10 | 1.00 | 1922 |
| 2025-04-10 | STOK | 6.54 | 4.10 | 5.00 | 1922 |
| 2025-04-11 | STOK | 7.03 | 4.10 | 1.00 | 1934 |
| 2025-04-14 | STOK | 7.58 | 4.09 | 5.00 | 1935 |
| 2025-04-15 | STOK | 7.75 | 4.05 | 0.57 | 1920 |
| 2025-04-16 | STOK | 7.57 | 4.05 | 0.57 | 1920 |
| 2025-04-17 | STOK | 7.68 | 4.05 | 0.57 | 1920 |
| 2025-04-18 | STOK | 7.69 | 3.80 | 0.00 | 1970 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-20 | STOK | 8.33 | 11.6 | - | -2.04 |
| 2025-03-21 | STOK | 8.15 | 11.6 | - | -1.31 |
| 2025-03-24 | STOK | 8.29 | 15.1 | - | -1.74 |
| 2025-03-25 | STOK | 7.74 | 15.1 | - | -1.74 |
| 2025-03-26 | STOK | 7.40 | 15.1 | - | -1.74 |
| 2025-03-27 | STOK | 7.44 | 15.1 | - | -1.74 |
| 2025-03-28 | STOK | 7.21 | 87.4 | - | -1.38 |
| 2025-03-31 | STOK | 6.65 | 87.4 | - | -1.38 |
| 2025-04-01 | STOK | 6.23 | 87.4 | - | -1.38 |
| 2025-04-02 | STOK | 6.60 | 87.4 | - | -1.38 |
| 2025-04-03 | STOK | 6.30 | 87.4 | - | -1.38 |
| 2025-04-04 | STOK | 5.93 | 78.9 | - | -1.34 |
| 2025-04-07 | STOK | 5.99 | 78.9 | - | -1.34 |
| 2025-04-08 | STOK | 5.90 | 78.9 | - | -1.34 |
| 2025-04-09 | STOK | 6.43 | 78.9 | - | -1.34 |
| 2025-04-10 | STOK | 6.53 | 78.9 | - | -1.34 |
| 2025-04-11 | STOK | 7.02 | 78.9 | - | -1.34 |
| 2025-04-14 | STOK | 7.56 | 78.9 | - | -1.34 |
| 2025-04-15 | STOK | 7.75 | 78.9 | - | -1.34 |
| 2025-04-16 | STOK | 7.56 | 78.9 | - | -1.34 |
| 2025-04-17 | STOK | 7.69 | 78.9 | - | -1.34 |
| 2025-04-18 | STOK | 7.69 | 78.9 | - | -1.35 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-20 | STOK | -24.93 | -0.49 | 27.35 |
| 2025-03-21 | STOK | -24.68 | -0.49 | 27.35 |
| 2025-03-24 | STOK | -14.60 | -0.46 | 26.78 |
| 2025-03-25 | STOK | -14.54 | -0.46 | 26.83 |
| 2025-03-26 | STOK | -14.54 | -0.46 | 28.12 |
| 2025-03-27 | STOK | -14.54 | -0.46 | 28.12 |
| 2025-03-28 | STOK | -14.54 | -0.46 | 28.12 |
| 2025-03-31 | STOK | -14.54 | -0.46 | 28.12 |
| 2025-04-01 | STOK | -14.54 | -0.46 | 28.12 |
| 2025-04-02 | STOK | -14.54 | -0.46 | 28.12 |
| 2025-04-03 | STOK | -14.48 | -0.46 | 28.12 |
| 2025-04-04 | STOK | -14.48 | -0.46 | 28.12 |
| 2025-04-07 | STOK | -14.48 | -0.47 | 28.12 |
| 2025-04-08 | STOK | -14.47 | -0.47 | 28.12 |
| 2025-04-09 | STOK | -14.47 | -0.47 | 28.12 |
| 2025-04-10 | STOK | -14.47 | -0.47 | 29.02 |
| 2025-04-11 | STOK | -14.47 | -0.47 | 29.02 |
| 2025-04-14 | STOK | -14.47 | -0.47 | 29.02 |
| 2025-04-15 | STOK | -14.47 | -0.47 | 29.02 |
| 2025-04-16 | STOK | -14.47 | -0.47 | 29.02 |
| 2025-04-17 | STOK | -14.47 | -0.47 | 29.02 |
| 2025-04-18 | STOK | -14.47 | -0.47 | 29.02 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.18
Avg. EPS Est. Current Quarter
-0.07
Avg. EPS Est. Next Quarter
-0.36
Insider Transactions
-14.47
Institutional Transactions
-0.47
Beta
1.15
Average Sales Estimate Current Quarter
27
Average Sales Estimate Next Quarter
12
Fair Value
Quality Score
23
Growth Score
30
Sentiment Score
72
Actual DrawDown %
89.3
Max Drawdown 5-Year %
-95.2
Target Price
23.88
P/E
Forward P/E
PEG
P/S
11.38
P/B
1.81
P/Free Cash Flow
EPS
-1.68
Average EPS Est. Cur. Y
-1.35
EPS Next Y. (Est.)
-2
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-243.42
Relative Volume
1
Return on Equity vs Sector %
-58.8
Return on Equity vs Industry %
-45.4
EPS 1 7Days Diff
EPS 1 30Days Diff
0.77
EBIT Estimation
Stoke Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 128
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
stock quote shares STOK – Stoke Therapeutics, Inc. Stock Price stock today
news today STOK – Stoke Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch STOK – Stoke Therapeutics, Inc. yahoo finance google finance
stock history STOK – Stoke Therapeutics, Inc. invest stock market
stock prices STOK premarket after hours
ticker STOK fair value insiders trading